The oral multikinase VEGFR*1, 2, and 3 inhibitor pazopanib failed to improve overall survival (OS) in advanced ovarian cancer patients who have not progressed following first-line chemotherapy, according to the results of the AGO-OVAR16** study.
Use of regional anaesthesia-analgesia using paravertebral blocks and the anaesthetic propofol does not lead to a lower risk of breast cancer recurrence after potentially curative surgery as compared with general anaesthesia with the volatile anaesthetic sevoflurane and opioid analgesia, according to a study.
The combination of gemcitabine plus S-1 (GS) is as good as gemcitabine plus cisplatin (GC), the current standard treatment for advanced biliary tract cancer (BTC), according to data from the phase III FUGA-BT trial (JCOG1113). However, the former does not require concomitant hydration therapy and should be considered a new treatment option for patients with advanced or recurrent BTC.
According to the results of a systematic review and network meta-analysis, osimertinib and gefitinib plus pemetrexed-based chemotherapy appear to be the best first-line treatments, as shown by their most favourable progression-free (PFS) and overall survival (OS), for patients with advanced epidermal growth factor receptor (EGFR)-mutated nonsmall cell lung cancer (NSCLC).
Chronic myeloid leukaemia (CML) patients treated with second- or third-generation tyrosine kinase inhibitors (TKI) face considerable long-term cardiovascular (CV) mortality risks, a new study has found.
A year-long course of supervised exercise intervention does not appear to yield large positive effects on breast cancer biomarkers in physically inactive menopausal women, although greater fat loss with exercise does lead to more favourable biomarker trends, according to data from the Breast Cancer and Exercise Trial in Alberta (BETA).
Postprostatectomy intensity-modulated radiation therapy leads to favourable long-term quality of life (QoL) among prostate cancer patients without bearing substantial late toxicities, a recent study has found.
Adding the PD-L1 inhibitor atezolizumab to first-line platinum-based chemotherapy significantly prolonged progression-free survival (PFS) compared with chemotherapy alone in patients with metastatic urothelial carcinoma (mUC), according to the IMvigor130* study presented at the ESMO Congress 2019.
The triplet regimen of encorafenib, binimetinib and cetuximab provides significant and clinically relevant benefits in overall survival (OS) and objective response rate (ORR) in patients with BRAFV600E-mutated metastatic colorectal cancer (mCRC) who experience disease progression after one or two previous regimens, according to results of an interim analysis of the BEACON CRC trial.
New drug applications approved by US FDA as of 01 - 15 November 2019 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.